Vycor Medical's NovaVision Launches its European Internet-Delivered Therapy Suite at the 3rd European Conference of NeuroRehabilitation

BOCA RATON, Florida and MAGDEBURG, Germany, November 30, 2015 /PRNewswire/ --

NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that is launching the European version of its Internet-delivered NovaVision Therapy Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) in Vienna, Austria to be held December 1-4, 2015.

NovaVision's therapy suite consists of Vision Restoration Therapy (VRT) and NeuroEyeCoach, an eye-movement compensation therapy. The therapy suite, which is delivered directly to patients' computers via the Internet, is designed to provide broad benefits to those who suffer from vision disorders due to stroke or other brain injury. NovaVision has today released the therapy suite, in both German and English, and is now in a position to take on and treat new patients globally in those languages from its offices in the US, Germany and the UK.

The ECNR is the European-wide body of national NeuroRehabilitation societies with a mission to promote the medical and social well-being of those with disabling neurological disorders and to further research, education and scientific dialogue in the field. It is considered to be a key European body in neurorehabilitation research and attracts leading speakers from across Europe. The theme of the 2015 congress is "Transition and Translation: Two challenges for NeuroRehabilitation" and the program will present the latest progresses in neurorehabilitation research and their implementation in practice.

Professor Josef Zihl, a NovaVision Scientific Advisor and prof. Emeritius in the Dept. of Psychology at the Univ. of Munich and formerly of the Max Planck Institute, will be presenting on December 1 a talk entitled "Rehabilitation of Visual Perception Disorders". On December 3, Prof. Zihl, together with Professor Arash Sahraie, Professor and Chair in Vision Sciences at the University of Aberdeen, UK, will present jointly a talk entitled: "Rehabilitation of patients with visual field loss: restitution vs. compensation". Prof. Sahraie developed a NovaVision restoration therapy called Neuro-Eye Therapy, and both Prof. Sahraie and Prof. Zihl developed NeuroEyeCoach, the compensation component of the new therapy suite.

Adrian Liddell, chairman of Vycor and managing director of NovaVision in Germany, commented: "The launch of our Internet-delivered Therapy Suite in Europe enables us to offer the most comprehensive and affordable therapy solution available today to patients and physicians out of our offices in Magdeburg, Germany and Aberdeen, UK. Our scalable Vision Therapy Suite targets a multi-billion dollar market opportunity in Europe, where it can help the large number people who suffer vision related disorders following a stroke or brain injury. We are delighted to be able to launch the European Therapy Suite at this important congress attended by Professors Zihl and Sahraie, who have been instrumental in its development."

In Europe, there are over 1.1 million new strokes and about 1 million hospitalized brain injury cases every year, and up to 30% of these may suffer a vision disorder. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision. The two therapies provided in the Therapy Suite are therefore highly complementary. NovaVision will also provide German and English language Professional models, enabling physicians to register and monitor patients and also for clinics and centers to treat patients in-clinic under their supervision.

About Vycor Medical, Inc. 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS, see VBAS Video.

NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke, or brain injury. NovaVision's family of therapies both restore and compensate for lost vision. NovaVision's VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S. NeuroEyeCoach is a compensation therapy registered in the US as a Class I 510(k) exempt device, VRT and NeuroEyeCoach are highly complementary and provided to patients in an Internet-delivered suite, to ensure broad benefits to patients. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, visit http://www.vycormedical.com, http://www.vycorvbas.com or http://www.novavision.com.    

Investor Relations:
Liolios Group, Inc.
Ronald A. Both
Tel +1-949-574-3860
[email protected]

SOURCE Vycor Medical, Inc.